October 01, 2018
WELLESLEY, Mass., Oct. 1, 2018 – Proteomics is rapidly transitioning from R&D into applied fields such as diagnostics. Mass spectrometry and biochips are benefiting from an explosion of new proteomics content. An updated BCC Research study projects that the global market for proteomics will reach $16.8 billion in 2022, examining it by technologies, uses in drug discovery and development, clinical applications and end-user industries.
Proteomics content emerging from large-scale genomic and proteomic initiatives is driving the discovery of novel biomarkers that are important in the diagnosis of conditions such as cancer, myocardial infarction and congestive heart failure. Novel technologies are also driving proteomics applications. Such innovations include the increasing miniaturization and integration in biochips, and improvements in mass spectrometry workflows and instruments. From $7.9 billion in 2017, a five-year compound annual growth rate of 16.2% is projected, according to BCC Research’s report Proteomics: Technologies and Global Markets.
Key factors driving growth in the proteomics industry include an expanding pipeline of diagnostics using proteomics mass spectrometry and biochip platforms; increasing pharmaceutical and biotech R&D expenditures; growing demand for personalized medicine; corporate deal-making between proteomics biotechnology companies and large pharma/instrument suppliers; and genomics-driven discoveries.
“The proteomics industry contains a diverse set of platforms, market segments, and competitors. The industry is attractive because it complements the large genomics industry, providing additional data for understanding biological systems,” said BCC Research analyst Bhavna Joshi. “Innovation within the industry is a source of competitive advantage and is able to drive adoption among users in the life sciences.”
Proteomics Transitions from Research to Clinic
Proteomics has proven to be valuable in life science research applications for identifying multiple proteins, profiling protein expression, identifying proteins in a particular state in an organism, and deciphering protein interactions in living organisms. The high sensitivity and accuracy of mass spectrometric analysis of proteomes and high reliability of protein-based biochips for detection of multiple biomarkers have leveraged wide adoption of proteomics in personalized medicine.
Editors/reporters requesting analyst interviews should contact Eric Surber at email@example.com.
Proteomics: Technologies and Global Markets( BIO034E )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.